[
1. CHEN LT., MARTINELLI E., CHENG AL., PENTHEROUDAKIS G., QIN S., BHATTACHARYYA GS., et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOSESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31(3):334–351.10.1016/j.annonc.2019.12.00132067677
]Search in Google Scholar
[
2. HASAN I., SULAIMAN AS., GANI RA., LESMANA CR. Risk factors for hepatocellular carcinoma and its mortality rate: a multicenter study in Indonesia. Arch Cancer Res. 2019;7(1):2.
]Search in Google Scholar
[
3. LOHO IM., SIREGAR L., WASPODO AS., HASAN I. Current practice of hepatocellular carcinoma surveillance. Acta Med Indones. 2018;50(4):353–360.
]Search in Google Scholar
[
4. SHU H., LI W., SHANG S., QIN X., ZHANG S., LIU Y. Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1. Discov Med. 2017;23(126):163–168.
]Search in Google Scholar
[
5. PAUL SB., GULATI MS., SREENIVAS V., MADAN K., GUPTA AK., MUKHOPADHYAY S., et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha- fetoprotein. J Oncol. 2007;72(suppl 1):117–123.10.1159/00011171718087192
]Search in Google Scholar
[
6. YANG JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol. 2019;25(4): 335–34310.3350/cmh.2019.0010693312330924328
]Search in Google Scholar
[
7. DUAN J., WU Y., LIU J., ZHANG J., FU Z., FENG T., et al. Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine. J Hepatocell Carcinoma. 2019;6:151–166.10.2147/JHC.S224849680578731696097
]Search in Google Scholar
[
8. OCKER M. Biomarkers for hepatocellular carcinoma: what’s new on the horizon? World J Gastroenterol. 2018;24(35):3974–3979.10.3748/wjg.v24.i35.3974614842430254402
]Search in Google Scholar
[
9. HODEIB H., ELSHORA O., SELIM A., SABRY NM., ELASHRY HM. Serum midkine and osteopontin levels as diagnostic biomarkers of hepatocellular carcinoma. Electron Physician. 2017;9(1):3492–3498.10.19082/3492530848628243398
]Search in Google Scholar
[
10. WANG P., MAO YM., ZHAO CN., WANG JB., LI XM., YE DQ., et al. Association of midkine and pleiotrophin gene polymorphisms with systemic lupus erythematosus susceptibility in Chinese Han population. Front Immunol. 2020;11:110.10.3389/fimmu.2020.00110704679432153561
]Search in Google Scholar
[
11. EI-EDEL RH., TAWFIK GA., NORELDIN RI., EL-JAKY MA., EISAA DA. Evaluation of serum midkine as a novel marker in hepatocellular carcinomas. Menoufia Med J. 2018;31(3):1094.
]Search in Google Scholar
[
12. PARKIN DM., BRAY F., FERLAY J., PISANI P. Global cancer statistics, 2002. Ca-Cancer J Clin. 2005;55(2):74–108.10.3322/canjclin.55.2.7415761078
]Search in Google Scholar
[
13. KINOSHITA A., ONODA H., FUSHIYA N., KOIKE K., NISHINO H., TAJIRI H. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol. 2015;7(3): 406–424.10.4254/wjh.v7.i3.406438116625848467
]Search in Google Scholar
[
14. RICHANI M., KOLLY P., KNOEPFLI M., HERRMANN E., ZWEIFEL M., TENGG-KOBLIGK HV., et al. Treatment allocation in hepatocellular carcinoma: assessment of the BCLC algorithm. Ann Hepatol. 2016;15(1):82–90.10.5604/16652681.118423326626644
]Search in Google Scholar
[
15. MARRERO JA., KULIK LM., SIRLIN CB., ZHU AX., FINN RS., ABECASSIS MM., et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750.10.1002/hep.2991329624699
]Search in Google Scholar
[
16. TELLAPURI S., SUTPHIN PD., BEG MS., SINGAL AG., KALVA SP. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol. 2018;37(6):481–491.10.1007/s12664-018-0915-030593649
]Search in Google Scholar
[
17. DOYLE A., SHERMAN M. Liver biopsy for hepatocelullar carcinoma (HCC): should this be a routine? Curr Hepatol Rep. 2017;16:46–50.
]Search in Google Scholar
[
18. HNASKO R. ELISA: Methods and protocols. USA; New York: Humana Press, 2019.
]Search in Google Scholar
[
19. WORLD HEALTH ORGANIZATION. World cancer report 2014. http://www.who.int// (accessed 23 May 2020)
]Search in Google Scholar
[
20. BALOGH J., VICTOR III D., ASHAM EH., BURROUGHS SG., BOKTOUR M., SAHARIA A., et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3: 41–53.10.2147/JHC.S61146506356127785449
]Search in Google Scholar
[
21. MANIERI E., HERRERA-MELLE L., MORA A., TOMÁS-LOBA A., LEIVA-VEGA L., FERNÁNDEZ DI., et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med. 2019;216(5):1108–1119.10.1084/jem.20181288650421530944152
]Search in Google Scholar
[
22. SAXENA NK., FU PP., NAGALINGAM A., WANG J., HANDY J., COHEN C., et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. J Gastroenterol. 2010;139(5):1762–1773.
]Search in Google Scholar
[
23. TANGKIJVANICH P., MAHACHAI V., SUWANGOOL P., POOVORAWAN Y. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. World J Gastroenterol. 2004;10(11): 1547–1550.10.3748/wjg.v10.i11.1547457275115162522
]Search in Google Scholar
[
24. EL-SERAG HB., RUDOLPH KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. J Gastroenterol. 2007;132:2557–2576.10.1053/j.gastro.2007.04.06117570226
]Search in Google Scholar
[
25. MAZZAFERRO V., REGALIA E., DOCI R., ANDREOLA S., PULVIRENTI A., BOZZETTI F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–700.10.1056/NEJM1996031433411048594428
]Search in Google Scholar
[
26. TAKAYAMA T., MAKUUCHI M., KOJIRO M., LAUWERS GY., ADAMS RB., WILSON SR., et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol. 2008;15:972–978.10.1245/s10434-007-9685-018236118
]Search in Google Scholar
[
27. KO YS., BAE JH., SINN DH., GWAK GY., KANG W., PAIK YH., et al. The clinical significance of serum alpha-fetoprotein in diagnosing hepatocellular carcinoma in a health screening population. Korean J Gastroenterol. 2017;69(4):232–238.10.4166/kjg.2017.69.4.23228449425
]Search in Google Scholar
[
28. TZARTZEVA K., OBI J., RICH NE., PARIKH ND., MARRERO JA., YOPP A., et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. J Gastroenterol. 2018;154(6):1706–1718.10.1053/j.gastro.2018.01.064592781829425931
]Search in Google Scholar
[
29. JING X., CUI X., LIANG H., HAO C., HAN C. Diagnostic accuracy of ELISA for detecting serum midkine in cancer patients. PLoS One. 2017;12(7): e0180511.10.1371/journal.pone.0180511550156028686647
]Search in Google Scholar
[
30. ZHANG BH., LI B., KONG LX., YAN LN., YANG JY. Diagnostic accuracy of midkine on hepatocellular carcinoma: A meta-analysis. PLoS One. 2019; 14(10): e0223514.10.1371/journal.pone.0223514678658531600291
]Search in Google Scholar
[
31. VONGSUVANH R., VAN DER POORTEN D., ISELI T., STRASSER SI., MCCAUGHAN GW., GEORGE J. midkine increases diagnostic yield in AFP negative and NASH-related hepatocellular carcinoma. PLoS One. 2016;11(5): e0155800.10.1371/journal.pone.0155800487879327219517
]Search in Google Scholar
[
32. SHAHEEN KY., ABDEL-MAGEED AI., SAFWAT E., ALBREEDY AM. The value of serum midkine level in diagnosis of hepatocellular carcinoma. Int J Hepatol. 2015; 2015:146389.
]Search in Google Scholar
[
33. NAULT J-C. Midkine as a new diagnostic tool in hepatocellular carcinoma. Transl Gastrointest Cancer. 2014;3(2):100–102.
]Search in Google Scholar
[
34. ZHANG BH., LI B., KONG LX., YAN LN., YANG JY. Diagnostic accuracy of midkine on hepatocellular carcinoma: A meta-analysis. PLoS One. 2019; 14(10):e0223514.10.1371/journal.pone.0223514
]Search in Google Scholar
[
35. LU Q., CAO H., LV C., WANG X., CAO S. Comparison of diagnostic accuracy of midkine and AFP for detecting hepatocellular carcinoma: A systematic review and meta-analysis. Biosci Rep. 2020;40(3):BSR20192424.10.1042/BSR20192424708732632039435
]Search in Google Scholar
[
36. ZHAO ZQ., YANG S., LU HS. Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival. Mol Med Rep. 2012;5(2):415–419.
]Search in Google Scholar
[
37. ZHU WW., GUO JJ., GUO L., JIA HL., ZHU M., ZHANG JB., et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19(14):3944–3954.10.1158/1078-0432.CCR-12-3363631449123719264
]Search in Google Scholar
[
38. SHIMADA H., NABEYA Y., TAGAWA M., OKAZUMI SI., MATSUBARA H., KADOMATSU K., et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 2003;94(7):628–632.10.1111/j.1349-7006.2003.tb01494.x12841873
]Search in Google Scholar